Home › News and Press › Press releases

News and Press releases

View all News Press releases

Oxcia AB (publ) publishes interim report for the second quarter 2023

August 25, 2023 · Press releases

OXC-101 as a novel therapy for AML will be presented at 18[th] Annual Congress of International Drug Discovert Science & Technology, Amsterdam 12-14 July, 2023

August 23, 2023 · Press releases

OXC-101 as a novel therapy for AML will be presented at 18[th] Annual Congress of International Drug Discovery Science & Technology, Amsterdam 12-14 July, 2023

June 30, 2023 · Press releases

Oxcia AB (publ) publishes annual report

May 16, 2023 · Press releases

Oxcia AB (publ) publishes interim report fort the first quarter 2023

April 26, 2023 · Press releases

Oxcia has been awarded a grant of 3 million SEK for a study in refractory AML patients

April 3, 2023 · Press releases

Three abstracts on OXC-101 selected for poster presentations at AACR 2023

March 30, 2023 · Press releases

New pre-clinical study shows that OXC-201 may be a promising treatment for IPF (pulmonary fibrosis)

March 2, 2023 · Press releases

The EIC has awarded Oxcia AB with a EIC transition grant of 2.5 million Euros for development of OXC-201.

February 24, 2023 · Press releases

Oxcia AB publishes Year-End Report for 2022

February 15, 2023 · Press releases

Data show OXC-201 may be a promising treatment for allergic asthma.

October 21, 2022 · Press releases

Enrolment completed and recommended phase II dose reached for OXC-101

October 14, 2022 · Press releases

Search